Tweets
#JulyIssue | This #Review provides an overview of the immunological, clinical and pathophysiological features of anti-citrullinated protein antibodies in #RheumatoidArthritis
Check it out here: https://t.co/dzMHF9ETyu https://t.co/hRzkLp6K9g
Links:
NatRevRheumatol @NatRevRheumatol ( View Tweet )
1 year 7 months ago
Prevention of Psoriatic Arthritis
Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.
https://t.co/BHnTciKU1f https://t.co/P7gDZUSGRw
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
JAK Inhibitors in GCA
Trials are underway evaluating the potential benefits of JAKi in GCA patients who are refractory to standards of care. An observational real-world analysis of a small worldwide cohort suggests the utility of JAKi in GCA.
https://t.co/d4IsqBgkxQ https://t.co/PIDhwzgNym
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Difficult-to-Treat Psoriasis
This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics.
https://t.co/OWzmYShqBs https://t.co/u1995MAB15
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Low Back Pain? Take a Walk!
A randomised controlled trial of adults with recurrent low back pain (LBP) has shown that a program of progressive walking and education intervention significantly reduced low back pain recurrence.
https://t.co/FTm69VviD1 https://t.co/q53EIxAc1J
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
RT: @synovialjoints In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
RT: @aurelierheumo
TOLERA trial in RA
RTX/ABA sequence versus RTX alone
10pts each group
Primary outcome was ambitious: ACPA seroconversion
No difference between ttmts (and also no seroconversion)
No diff in disease activity
No diff in ACPA change wt wk52
OP0069 #EULAR2024
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
RT @yuz6yusof #EULAR2024 Cutaneous #lupus is variable & can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing Deucravacitinib (Tyk2-i) led to improvement & sustained CLASI-50 response in all subtypes (ACLE, SCLE, Chonic and Discoid) #EULARBEST
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Vilobelimab, an anticomplement factor 5a (C5a) antibody, shown in this case report to be effective in (difficult to treat) pyoderma gangrenosum. https://t.co/P241Knoco6 https://t.co/hrCxOv8SEA
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Prevention of Psoriatic Arthritis
Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.
https://t.co/DQJ5AcwchL https://t.co/lHtCt720D9
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Digital Rheumatology
Dr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria.
https://t.co/9twSiXYL3N https://t.co/9vz77SrVLt
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Late “Breaking”: Reducing Osteoporotic Fractures in Postmenopausal Women
Dr. Janet Pope discusses abstract POS0583 presented at Eular 2024 in Vienna, Austria.
https://t.co/HIXV4EUkJb https://t.co/p38e6pzAvC
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
